8-K: Century Therapeutics Advances T1D, Autoimmune Cell Therapies

Century Therapeutics, Inc. provides an update on its iPSC-derived cell therapy pipeline, highlighting progress in Type 1 Diabetes and autoimmune diseases with its Allo-Evasion technology.

Summary

• Century Therapeutics is leveraging its Cell Foundry to generate fully functional cells at scale and its Allo-Evasion technology to enable cells to co-exist with a patient's immune system, enhancing persistence and potential for re-dosing.
• The company is advancing CNTY-813, an iPSC-derived beta islet cell replacement therapy for Type 1 Diabetes, which is currently in IND-enabling studies with preclinical data supporting potential for a functional cure.
• CNTY-308, an iPSC-derived CD19-targeted CAR-iT for B-cell-mediated diseases, is also in IND-enabling studies and is expected to enter the clinic in 2026.
• Patient enrollment is ongoing for CNTY-101, a CAR-iNK cell therapy, in the Phase 1/2 CARAMEL Investigator-Sponsored Trial (IST) for autoimmune diseases, with preliminary clinical data expected in 2026.
• The company has extended its cash runway beyond planned key clinical milestones, providing financial stability for upcoming development phases.
• Preclinical data for CNTY-813 demonstrates highly potent and pure iPSC-derived beta islet cells that provide functional glucose control and persist for over 4 months in T1D mice, without systemic immunosuppression due to Allo-Evasion 5.0.
• Preliminary data from the CARAMEL IST for CNTY-101 shows the therapy is generally well-tolerated, with one Grade 1 Cytokine Release Syndrome (CRS) event and early efficacy signals including improved mRSS and deep B cell depletion in a systemic sclerosis patient.

Sentiment

Score: 8

Explanation: The filing presents strong positive updates on pipeline progress, promising preclinical data for key assets, encouraging early clinical data, and an extended cash runway. These indicate significant advancements and potential for future value creation.

Positives

• Cash runway extended beyond planned key clinical milestones, providing financial stability.
• Advancing lead iPSC-derived cell therapies (CNTY-813, CNTY-308, CNTY-101) toward the clinic, demonstrating pipeline progress.
• CNTY-813 shows strong preclinical data with potential for functional cure in Type 1 Diabetes, including functional glucose control and persistence for over 4 months in mice without systemic immunosuppression.
• Allo-Evasion 5.0 technology provides broad protection from host immune cells (T-cells, NK-cells, and humoral immunity), addressing a critical challenge in allogeneic cell therapies.
• CNTY-308 iPSC-CAR-T cells demonstrate comparable function to primary CAR-T cells in preclinical studies, including high functional persistence and tumor control.
• CNTY-101 Phase 1/2 CARAMEL IST is actively enrolling patients and shows promising preliminary safety and early efficacy data, including general tolerability and deep B cell depletion.
• Established in-house manufacturing facility (53,000 sq ft cGMP) enables scalable, cost-effective production and maintains proprietary know-how.

Risks

• Ability to successfully advance current and future product candidates through development activities, preclinical studies, and clinical trials.
• Ability to progress product candidates through clinical development and meet development milestones on anticipated timelines.
• Uncertainties inherent in the results of preliminary data, preclinical studies, and earlier-stage clinical trials, which may not be predictive of final results or the results of later-stage clinical trials.
• Ability to obtain clearance of future Investigational New Drug (IND) or Clinical Trial Application (CTA) submissions and commence and complete clinical trials on expected timelines, or at all.
• Reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of product candidates.
• The timing, scope, and likelihood of regulatory filings and approvals, including final regulatory approval of product candidates.
• The impact of geopolitical issues, trade disputes and tariffs, banking instability, and inflation on business and operations, supply chain, and labor force.
• The performance of third parties in connection with the development of product candidates, including third parties conducting clinical trials as well as third-party suppliers and manufacturers.
• Ability to successfully commercialize product candidates and develop sales and marketing capabilities, if product candidates are approved.
• Ability to recruit and maintain key members of management.
• Ability to maintain and successfully enforce adequate intellectual property protection.

Future Outlook

Century Therapeutics plans to submit an IND for CNTY-813 in 2026, with initial clinical data anticipated in 2027. The CNTY-308 T cell program is expected to enter the clinic in 2026, and preliminary clinical data from the Phase 1/2 CARAMEL IST for CNTY-101 is expected in 2026. The company aims to continue evolving its Allo-Evasion technology to enhance holistic protection from major immunity pathways and deliver a successful Type 1 Diabetes cell replacement therapy that reduces or eliminates the need for chronic immunosuppression.

Management Comments

• Brent Pfeiffenberger, Pharm.D., President and Chief Executive Officer, signed the report, indicating management's endorsement of the presented updates.
• Management believes the Cell Foundry generates fully functional cells at scale and that Allo-Evasion allows cells to co-exist with a patient's immune system, enabling enhanced persistence and potential for re-dosing of therapy.
• Management states that Century is uniquely positioned to deliver a successful Type 1 Diabetes cell replacement therapy.

Industry Context

Type 1 Diabetes represents a significant global market with approximately 9 million patients worldwide and a high unmet medical need, despite existing insulin therapies. While beta islet cell replacement has a validated clinical proof-of-concept, its adoption is severely limited by cell source availability and the necessity for chronic immunosuppression. Current stem-cell derived islet therapies, such as Vertex's VX-880, have demonstrated functional benefits and scalability but still require immunosuppression. Century's Allo-Evasion technology aims to address this critical limitation, potentially offering a transformative therapy. In autoimmune diseases, the emerging positive data from autologous CAR T cell therapies supports the development of more accessible allogeneic CAR iT cells, a space Century is targeting with CNTY-308 and CNTY-101, building on encouraging CAR-NK data.

Comparison to Industry Standards

• **Cadaveric Islets**: While providing insulin independence for approximately 70% of patients for one year, cadaveric islet transplantation is severely limited by cell supply, logistics, and the mandatory requirement for chronic immunosuppression. CNTY-813 aims to overcome these limitations through scalable iPSC-derived cells and Allo-Evasion 5.0, potentially reducing or eliminating the need for immunosuppression.
• **Zimislecel (VX-880) by Vertex**: This stem-cell derived insulin-producing islet cell therapy has shown promising results, with 10 out of 12 patients achieving exogenous insulin freedom at 12 months. However, it still necessitates steroid-free immunosuppression. CNTY-813 differentiates itself by aiming to provide functional cure without systemic immunosuppression, a significant advantage.
• **Primary CAR-T cells**: Preclinical studies indicate that Century's iPSC-derived CAR-T cells (CNTY-308) are comparable to primary CAR-T cells in key functional aspects, including self-supported IL-2 secretion, high functional persistence (killing for >10 rounds, persisting in blood for 32+ days), and effective tumor control after in vivo rechallenge.

Stakeholder Impact

• **Shareholders**: Potential for significant positive impact due to strong pipeline progress, promising preclinical and early clinical data, and an extended cash runway, which could lead to increased company valuation and future returns.
• **Patients (Type 1 Diabetes, Autoimmune Diseases)**: Potential for transformative, potentially curative therapies that could significantly improve quality of life by reducing or eliminating the need for chronic immunosuppression and providing more accessible treatment options.
• **Employees**: Continued employment stability and potential for growth opportunities as the company's programs advance through clinical development and towards commercialization.
• **Regulatory Authorities**: Will be actively involved in the review and approval processes for IND/CTA submissions and subsequent clinical trial data, ensuring safety and efficacy standards are met.

Next Steps

• CNTY-813 IND submission planned for 2026.
• CNTY-308 T cell program expected to enter the clinic in 2026.
• CNTY-101 preliminary clinical data from Phase 1/2 CARAMEL IST expected in 2026.
• CNTY-813 initial clinical data expected in 2027.
• Continue advancing Allo-Evasion 5.0 toward the clinic for enhanced immune protection.
• Continue patient enrollment for CNTY-101 in the Phase 1/2 CARAMEL IST for autoimmune diseases.

Key Dates

Recommendation

Century Therapeutics is demonstrating significant progress across its key pipeline assets, particularly with promising preclinical data for CNTY-813 in Type 1 Diabetes and strong early clinical signals for CNTY-101 in autoimmune diseases. The proprietary Allo-Evasion technology addresses a critical challenge in allogeneic cell therapies by reducing the need for immunosuppression, which could be a major differentiator. The extended cash runway provides financial stability to reach key clinical milestones. These factors, combined with a scalable manufacturing platform, position Century Therapeutics for substantial future growth and potential market leadership in iPSC-derived cell therapies.

Keywords

Century Therapeutics, iPSC, Cell Therapy, Type 1 Diabetes, Autoimmune Disease, Allo-Evasion, CNTY-813, CNTY-308, CNTY-101, CAR-T, CAR-NK, Immunosuppression, Beta Islet Cells, Clinical Trials, Biotechnology, Pharmaceuticals